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THE WHITE HOUSE 
WASHINGTON 
April 10, 1962 
Dear Senator: 
In the me s sage I sent to the Congre s s on March 14, I calle d attention to 
the need for new legislative authority to advance and protect the interests 
of consumers in the marketing of drugs. 
S. 1552, which is now pending before your Committee, incorporates the 
major recommendations I made. It will strengthen and broaden existing 
laws in the food and drug field, contribute toward better, safer and less 
expensive medicine s, and establish a better system of enforcement. As 
you know, the bill is the outgrowth of twenty-eight months of intensive 
investigation and hearings by your Subcommittee on Antitrust and Monopoly. 
I believe that early passage of this legislation will substantially improve 
the ability of the drug industry to serve the Nation and help provide con-
sumers with quality drugs at low competitive prices. 
I understand that the members of the Subcommittee on Patents have de-
cided that the compulsory licensing feature of the legislation require s 
further study and consideration. I would hope that this would not, hO'Wever, 
delay enactment of the other provisions of the bill -- provisions which will 
establish neces sary safe guards to as sure the reliability and effecti vene ss 
of drugs placed on the market, provide for standardization of drug names, 
and thereby encourage physicians to pre scribe drugs by nonproprietary 
rather than by brand name s, require disclosure of adverse as well as 
beneficial effects of drugs in drug promotion, and assure consideration 
of therapeutic effectiveness in the granting of patents for drugs that are 
modifications of other drugs. 
The me ssage I sent to the Congre ss made several other sugge stions which, 
it would seem to me, might appropriately be included in the bill now before 
your Committee. They are: 
1. Drug manufacturers should be required to keep records on 
and report to the Department of Health, Education and Welfare 
any indications of adverse effects from the use of a new drug 
or antibiotic. 
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2. The Department of Health, Education and Welfare should 
be empowered to withdraw approval of a new drug on the basis 
of a substantial doubt of its efficacy or safety. 
3. The provisions requiring drug manufacturers to maintain 
facilities and controls to assure the reliability of their product, 
and to institute more effective inspection to determine whethe r 
drugs are being manufactured in accordance with the law, cannot 
feasibly be limited to a particular clas s of drugs and should 
therefore be made applicable to over-the-counter as well as 
prescription drugs. 
4. An enforceable system of preventing the illicit distribution 
of habit-forming barbiturates and amphetamines should be 
provided. 
The need for the se amendmends is based upon the accumulated years of 
experience of the Food and Drug Administration, and they appear to be 
properly within the scope of the subject matter dealt with in the extensive 
hearings of the Subcommittee on Antitrust and Monopoly. 
In addition, I recommend two minor procedural change s: 
1. In the section having to do with the rendering of advisory 
opinions by the Department of Health, Education and Welfare 
to the Patent Office on the therapeutic effect of modifications 
and combinations, I sugge st that the requirement providing the 
applicant with an opportunity for a plenary hearing be deleted. 
Under the provisions of S.1552 in its earlier form, the Secretary's 
finding was conclusive and therefore should have required a formal 
hearing. But since the bill in its pre sent form require s no bind-
ing decision to be made by the Secretary, the requirement of the 
hearing seems inappropriate and would tend to unduly delay the 
rendition of the Secretary1s purely advisory opinion to the Com-
missioner. The action of the Commissioner is, of course, 
subject to well established de novo judicial review. 
2. The provision requiring the filing of patent agreements with 
the Commissioner of Patents should more properly be in the 
form of an amendment to the Patent Act rather than the Sherman 
Act. 
I ' ( 
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I have asked the Department of Health, Education and Welfare to trans-
mit to you promptly any additional recommendations to strengthen, 
clarify, or improve the bill that it may have and that will not require 
additional hearings or substantially delay action on the bill. 
It would not appear that the consideration of the se proposed change s 
should occasion any further delay in the approval of this important measure. 
With the above changes, S. 1552 adequately deals with the most pressing 
problems in the drug field, and it is my sincere wish that it be enacted 
during the current session of the Congress. Your cooperation and assist-
ance to this end will be greatly appreciated. 
Honorable James O. Eastland 
United State s Senate 
Washington, D. C. 
Sincerely 
